Drugs / rAAV.hPDE6A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04611503 | Sep 2019 → Jul 2027 expected | retinitis pigmentosa | STZ eyetrial | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rAAV.hPDE6A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04611503 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “a recombinant adeno-associated viral (AAV) gene transfer vector” NCT04611503 ↗ |
| Route | Other | “The vector is given with a single subretinal injection.” NCT04611503 ↗ |